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Endothelial cells (ECs) are of great value for cell therapy, tissue engineering, and drug discovery. Obtaininghigh-quantity and -quality ECs
remains very challenging. Here, we report a method for the scalable manufacturing of ECs from human pluripotent stem cells (hPSCs).
hPSCs are expanded and differentiated into ECs in a 3D thermoreversible PNIPAAm-PEG hydrogel. The hydrogel protects cells from
hydrodynamic stresses in the culture vessel and prevents cells from excessive agglomeration, leading to high-culture efficiency including
high-viability (>90%), high-purity (>80%), and high-volumetric yield (2.03 107 cells/mL). These ECs (i.e., 3D-ECs) had similar properties
as ECs made using 2D culture systems (i.e., 2D-ECs). Genome-wide gene expression analysis showed that 3D-ECs had higher expression
of genes related to vasculature development, extracellular matrix, and glycolysis, while 2D-ECs had higher expression of genes related to
cell proliferation.
INTRODUCTION
Endothelial cells (ECs) are major components of blood
vessels (Carmeliet, 2001; Richards et al., 2010). They are
of great value for disease modeling, drug screening, cell
therapy, and tissue engineering (Heo et al., 2014; Huang
et al., 2013; Kang et al., 2013; Leung et al., 2016; Medina
et al., 2010; Moubarik et al., 2011; Patsch et al., 2015;
Schwarz et al., 2012; Stroncek et al., 2012). However,
obtaining large numbers of primary ECs for those applica-
tions, in particular for clinical applications (Arici et al.,
2015; Chao et al., 2014; den Dekker et al., 2011; Granton
et al., 2015; Matoba et al., 2008), is still challenging due
to their limited proliferation capacity and phenotype
changes during the in vitro culture (van Beijnum et al.,
2008; de Carvalho et al., 2015; Gui et al., 2009; Gumbleton
and Audus, 2001; Hayflick, 1965; Augustin-Voss et al.,
1993). Human pluripotent stem cells (hPSCs) provide a
potential solution to this challenge (Levenberg et al.,
2007). hPSCs, including human embryonic stem cells
(hESCs) (Thomson et al., 1998) and induced pluripotent
stem cells (iPSCs) (Takahashi et al., 2007; Yu et al., 2007),
have unlimited proliferation capacity and can be efficiently
differentiated into ECs through 3D embryonic body
(EB)-based (Condorelli et al., 2001; James et al., 2010; Lev-
enberg et al., 2002, 2007; Li et al., 2009a, 2009b; Nourse
et al., 2010) or 2D monolayer culture-based protocols
(Cao et al., 2013; Kane et al., 2010; Palpant et al., 2016;
Patsch et al., 2015; Vodyanik et al., 2005). In addition, cells
derived from patient-specific iPSCs have the patient’s ge-
netic information and can model many human diseases.
Further, they induce minimal immune response in vivo
(Lalit et al., 2014). These hPSC-derived ECs have the poten-
tial to provide unlimited cell sources for the applications.
While making small-scale hPSC-derived ECs in labora-
tories can be readily done (Giacomelli et al., 2017; Lian
et al., 2014; Orlova et al., 2014; Palpant et al., 2016; Zhang
et al., 2017a), generating or manufacturing large numbers
of ECs from hPSCs has not been achieved. Current 2D cul-
ture methods, in which cells are cultured as adherent cells
on 2D surfaces (e.g., cell culturing flasks), are labor, time,
and cost intensive, and not suitable for culturing cells on
a large scale (Jenkins and Farid, 2015; Kropp et al., 2017).
3D suspension culture methods (e.g., using stirred-tank
bioreactors), in which cells are suspended in an agitated
culturemedium, have been considered a potential solution
for scaling up the cell production (Jenkins and Farid, 2015;
Kropp et al., 2017; Lei and Schaffer, 2013). However, recent
research has shown that culturing cells on a large scale with
3D suspension cultures is also very challenging (Lei et al.,
2014; Serra et al., 2012; Steiner et al., 2010; Wurm, 2004).
hPSCs in 3D suspension cultures frequently aggregate to
form large cell agglomerates (Kropp et al., 2017). The
mass transport to cells located at the center of large
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agglomerates (e.g., >400 mm diameter) becomes difficult,
leading to slow cell growth, cell death, and uncontrolled
differentiation (Kropp et al., 2017). While agitating the
culture can reduce cell agglomeration, it also generates
hydrodynamic stresses, which are adverse to the cell’s
physiology (Fridley et al., 2012; Kinney et al., 2011; Kropp
et al., 2017). As a result, 3D suspension culturing has signif-
icant cell death, low cell growth, and low volumetric yield
(Lei and Schaffer, 2013). For instance, hPSCs typically
expand 4-fold in 4 days to yield around 1.0 3 106 to
2.0 3 106 cells/mL, which occupy 0.4% of the bioreactor
volume (Lei et al., 2014; Serra et al., 2012; Steiner et al.,
2010; Wurm, 2004).
To address the challenge, we previously developed a
scalable, efficient, and current Good Manufacturing
Practice (cGMP)-compliant method for expanding hPSCs
(Lei and Schaffer, 2013; Li et al., 2016; Lin et al., 2017).
The method, which was successfully repeated in this study
(Figures 1 and S2), uses a 3D thermoreversible hydrogel
(Mebiol Gel) as the scaffold. Single hPSCs are first sus-
pended in a liquid PNIPAAm-PEG polymer solution at
low temperature (e.g., 4C). Upon heating to 20C–37C,
the polymer solution forms an elastic hydrogel matrix,
resulting in single hPSCs encapsulated in the hydrogel
matrix. After culturing for about 4–5 days, these single
hPSCs clonally grow into spherical cell aggregates (spher-
oids) with very uniform size (Figures 1B, S2A, and S2D).
The hydrogel can be quickly liquefied through cooling
to4C to harvest the cells for the next passage (Figure 1A).
The hydrogel scaffold protects cells from hydrodynamic
stresses in the culture vessel and prevents cells from
excessive agglomeration, leading to high culture efficiency.
For instance, the hydrogel scaffold enables long-term,
serial expansion of hPSCs with a high cell viability
(e.g., >90%, Figures 1D, S2C, and S2F), growth rate (e.g.,
20-fold/5days, Figure 1E), yield (e.g., 2.0 3 107 cells/mL,
Figure 1F), and purity (>99%, Figure 1C, S2B, and S2E), all
of which offer considerable improvements over 3D
suspension cultures (Lei and Schaffer, 2013; Li et al.,
2016; Lin et al., 2017). We hypothesize that hPSCs can
also be differentiated into ECs in this culture system. In
this paper, we successfully tested the hypothesis. Together,
we developed a scalable bioprocess for making high-
quality ECs with high volumetric yield, high viability,
and high purity (>80%).
RESULTS
Differentiation of hPSCs into ECs in 2D Adherent
Cultures
We used H9 hESCs, iPSCs reprogrammed from human
dermal fibroblasts (i.e., Fib-iPSCs), and iPSCs reprog-
rammed from mesenchymal stem cells (i.e., MSC-iPSCs)
(Park et al., 2008), for this study. All formed compact col-
onies when cultured on Matrigel-coated plates in the
chemical-defined Essential 8 (E8) medium (Figures S1A,
S1E, and S1I). They expressed pluripotency makers
OCT3/4 and NANOG (Figures S1B, S1F, and S1J), and could
be differentiated into all three germ layer cells (e.g.,
NESTIN+ ectodermal, a-SMA+ mesodermal, and HNF-3b+
endodermal cells) in EB assay (Figures S1C, S1G, and
S1K). They also formed teratomas containing all three
germ layer tissues in immunodeficient mice (Figures S1D,
S1H, and S1L).
Patsch et al. (2015) recently reported a protocol that
could efficiently generate ECs from hPSCs in 6 days in 2D
cultures. This protocol is simple and quick, and thus it is
very appealing for making high-quantity ECs. We success-
fully repeated this protocol with our H9s and iPSCs (Fig-
ure S3). The produced ECs had the typical EC cobblestone
morphology (Figures S3B and S3H). Immunostaining
showed that the majority of these cells expressed the EC
markers PECAM1 (or CD31) and VE-Cadherin (or CD144)
(Figures S3C and S3I). Flow cytometry analysis showed
that about 80% cells were positive for the two markers
(Figures S3D and S3J). A small fraction of produced
cells was positive for SM22A and CD140b, markers for
smooth muscle cells (Figures S3E, S3F, and S3K). We did
not detect any undifferentiated OCT3/4+ and NANOG+
hPSCs (Figures S3G and S3L). H9s and iPSCs had similar
outcomes (Figure S3). Our results were very similar to these
reported by Patsch and Cowan, indicating the robustness
of the differentiation protocol (Patsch et al., 2015). We
termed ECs made in 2D culturing as 2D-ECs.
Differentiation of hPSCs into ECs in 3D
Thermoreversible PNIPAAm-PEG Hydrogels
We then applied the protocol to differentiate hPSCs in the
3D thermoreversible hydrogels (Figure 2A). Single hPSCs
were encapsulated into the gel and expanded for 5 days
to generated hPSC spheroids with a diameter of around
150 mm.Differentiationwas initiated on day 0 by switching
the expansionmedium to the differentiationmedium (Fig-
ure 2B). Live/dead cell staining showed that themajority of
cells on day 5 were live (Figure 2C). Immunostaining and
confocal imaging showed that the majority of cells in the
day 5 spheroids were positive for EC markers PECAM1
and VE-Cadherin (Figure 2D). ECs were uniformly distrib-
uted, and no cysts were found in the spheroids, indicating
no or little cell death in the spheroids. Flow cytometry
analysis found that about 84% of the cells were PECAM1+
and VE-Cadherin+ (Figure 2E). About 1.6 3 107 cells
and 2.0 3 107 cells were produced in each milliliter of
hydrogel on day 0 and 5, respectively (Figure 2F). Thus,
about 20 cells were generated from one input hPSC on
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day 5. When the day 5 EC spheroids were dissociated
into single cells and plated on Matrigel-coated plates at
high density, they formed tight cell-cell interactions (Fig-
ure 2G). Immunostaining detected small numbers of
SM22A+ cells (Figure 2H), and flow cytometry analysis
found that about 13.8% of cells were CD140b+ (Figure 2I).
Figure 1. Manufacture hPSC-Derived ECs in 3D Thermoreversible Hydrogels
(A) Illustration of the bioprocess. Single hPSCs are mixed with 10% PNIPAAm-PEG solution at low temperature (e.g., 4C), which forms an
elastic hydrogel at 37C. Single hPSCs clonally expand into uniform spheroids in the hydrogel in 5 days. Upon cooling to 4C, the hydrogel
is liquefied, and spheroids are harvested and dissociated into single cells for the next expansion (i). Once the targeted cell number is
reached, hPSCs are differentiated into ECs in the hydrogel (ii).
(B) Phase images of day 0, 1, 3, and 5 H9 hESCs. Scale bar, 200 mm.
(C) Immunostaining of day 5 H9 spheroids for pluripotency marker OCT3/4, NANOG, ALP, and SSEA4. Scale bar, 50 mm.
(D) Live/dead staining of harvested day 5 H9 spheroids. Scale bar, 200 mm.
(E and F) About 5-, 10-, and 20-fold expansion (E), yielding5, 10, and 20 million cells per milliliter of hydrogel (F) on day 3, 4, and 5, is
achieved for H9s, Fib-iPSCs, and MSC-iPSCs. Data are represented as mean ± SD of three independent replicates (n = 3).
456 Stem Cell Reports j Vol. 11 j 454–469 j August 14, 2018
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No undifferentiated OCT3/4+ and NANOG+ hPSCs were
detected (Figure 2J). The majority of cells were PECAM1+/
VE-Cadherin+ (Figure 2K). Fib-iPSCs and MSC-iPSCs had
similar outcomes (Figures S4 and S6). We found the differ-
entiation efficiencies in the 3D hydrogel and the conven-
tional 2D culture were very close (Figures 2 and S3). We
termed ECs made in the hydrogel and that had not been
cultured on any 2D surfaces as 3D-ECs.
Properties of hPSC-Derived ECs
Our culture system provides a 3D microenvironment for
hPSC growth and differentiation. Recent studies found
that the 3D microenvironment could alter the cell pheno-
type and functional properties compared with those
cultured in 2D (Zhang et al., 2017b; Zujur et al., 2017).
We thus asked if the 3D-ECs and 2D-ECs were similar in
phenotype, function, and gene expression. Using fluores-
cently labeled acetylated LDL and microscope imaging,
we found that they had a similar capacity to uptake lipids
(Figure 3A). In the classical tube formation assay, they
could form vascular network-like structures (Figure 3B).
Through quantification with the Angiogenesis Analyzer
of ImageJ (Fork et al., 2015), we found 3D-ECs had higher
tube length andbranching counts than2D-ECs (Figure 3C).
When ECs were co-cultured with vascular smooth muscle
cells, they could arrange in highly organized structures
(Figure 3D). The trans-endothelial electrical resistance
(TEER) analysis (Srinivasan et al., 2015) revealed that
both formed tight barriers as shown by the high TEER
value. The barrier tightness was disrupted by tumor
necrosis factor alpha, interleukin-1b (IL-1b), and vascular
endothelial growth factor A (VEGFA), as shown by a sharp
decrease of TEER values. Importantly, 3D-ECs and 2D-ECs
performed very similar to primary human umbilical vein
endothelial cells (HUVECs) (Figure 3E). To test the angio-
genic potential of 3D-ECs and 2D-ECs in vivo, we injected
them subcutaneously with aMatrigelmatrix into immuno-
deficient mice. H&E staining and immunostaining
revealed similar blood vessel density and structure in the
matrix for 3D-ECs and 2D-ECs (Figures 3F and 3G). We
also used qPCR to quantitatively analyze the expression
of a few EC-specific genes including the surface markers
(CD31, CD144, VWF, and CD34), growth factors (VEGFA,
VEGFB, and VEGFC), and extracellular matrix (ECM)
(FN and COL4A). The results showed that the 3D microen-
vironment enhanced the expression of these genes (Figures
3H and 3I). Similar results were found for iPSC-derived ECs
(Figure S5).
Whole Transcriptome Analysis of 3D-ECs and 2D-ECs
Derived from H9s
The above qPCR findings drove us to study the genome-
wide gene expression difference using RNA sequencing
(RNA-Seq). We sequenced the undifferentiated H9s,
3D-ECs, and 2D-ECs derived from H9s (three biological
replicates for each). Hierarchical clustering analysis
(Figure 4A) and principal component analysis (PCA) (Fig-
ure 4B) showed that 3D-ECs and 2D-ECs clustered closely
and were very different from H9s. The genome-wide gene
expression profile correlation coefficients between 3D-
ECs and 2D-ECs were >0.83, indicating similar global
gene expressions (Figures 4C and 4D). However, the separa-
tion of 2D-ECs and 3D-ECs in PC2 of the PCA indicated
that these cells had some differences in gene expressions
(Figure 4B), which drove us to perform detailed differential
gene expression analysis.
Differential gene expression analysis identified 919 genes
upregulated in 3D-ECs, and 718 genes upregulated in
2D-ECs (Data S1). Gene ontology term analysis showed
that genes enriched in 3D-ECs are related to vasculature
development, ECM assembly and cell adhesion, glycolysis,
and ephrin andNotch signaling. Genes enriched in 2D-ECs
are related to mitotic cell-cycle process genes and ECM
disassembly (Figure 5A). These results indicated that
2D-ECs adopted a proliferative phenotype, while the 3D
environment promoted vascular morphogenesis.
Detailed gene expression analysis (Data S2) showed the
following differences: (1) 3D-ECs had higher expression
of ECM genes including collagen (COL23A1, COL20A1,
COL13A1, COL11A2, COL6A6, COL6A3, COL14A1,
COL24A1, COL4A4, COL16A1, COL25A1, COL27A1,
COL5A1, COL6A5, COL4A3, COL7A1, COL4A6, and
Figure 2. Differentiate H9 hESCs into ECs in 3D Thermoreversible PNIPAAm-PEG Hydrogels
(A) Illustration of the differentiation protocol.
(B) Phase images of day 0, 3, and 5 cells. Scale bars, 100 mm.
(C) Live/Dead staining of harvested day 5 cells. Scale bars, 200 mm.
(D and E) Immunostaining (D) and flow cytometry analysis (E) of EC markers PECAM1 (or CD31) and VE-Cadherin (or CD 144) on day 5 cells.
Immunostaining of five slices of one day 5 spheroid for EC markers PECAM1 and VE-Cadherin. Scale bar, 50 mm.
(F)  2 3 107 ECs are produced per milliliter of hydrogel on day 5. Data are represented as mean ± SD of three independent replicates
(n = 3).
(G–K) The day 5 spheroids are dissociated into single cells and plated on 2D surface overnight. Phase image shows the cobblestone
morphology (G). Immunostaining and flow cytometry shows a small fraction of SM22A+ cells (H) and CD140b+ cells (I), respectively, but
no undifferentiated OCT3/4+/NANOG+ hPSCs (J). Majority cells are PECAM1+/VE-Cadherin+ (K). Scale bars, 50 mm.
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COL6A2); laminin (LAMC3, LAMB3, and LAMB4); integrin
(ITGA2, ITGB2, ITGB3, ITGA2B, ITGA6, ITGA10, ITGA11,
ITGB8, ITGA9, ITGAM, and ITGA5); other ECM compo-
nents (DCN, THBS2, HSPG2, FN1, and THSD1); and
proteases (MMP9, MMP23B, MMP24, MMP17, and
MMP16) (Figures 5B–5F); 2D-ECs had higher expression
of ECM genes including collagen (COL12A1, COL2A1,
COL8A2, COL21A1, and COL11A1); laminin (LAMC1);
integrin (ITGAL, ITGB6, ITGA7, and ITGB4); other ECM
components (EFEMP1, NTN1, and FBN1); and proteases
(MMP11, MMP1, TIMP3, TIMP2, and MMP15) (Figures
5B–5F). (2) 3D-ECs had higher expression of genes for
EC-secreted factors including MMP9, IGF1, TNFRSF10C,
VEGFA, CCL5, IGFBP1, IGFBP2, IL6, CXCL16, ANGPT1,
FGF10, ANGPT2, IL-1B, VEGFB, and ANG (Figures 5G–5J);
2D-ECs had higher expression of genes for EC-secreted
factors including CXCL1, CCL7, CXCL10, TGFA, CTGF,
CXCL2, CXCL6, HGF, CXCL11, CCL2, TIMP2, IL-8, and
BMP6 (Figures 5G–5J). (3) 3D-ECs had higher expression
of genes for glycolysis (Figure 5L), vasculature development
(Figure S7A), angiogenesis (Figures S7B and S7C), hypoxia
signaling (Figure S7D), ephrin (Figure S7E), NOTCH
signaling (Figure S7F), and Wnt signaling (Figure S7G).
(4) 2D-ECs had higher expression of genes for cell cycle
and proliferation (Figure 5K).
Wedid further tests to study if the differences found in the
RNA-seq data analysis could also be found in cell phenotype
or function assays. Western blotting analysis showed that
3D-ECs had higher expressions for CD31, CD144, FN,
NOTCH4, and ITGA2 than 2D-ECs (Figure 6A). Using Ki67
immunostaining and flow cytometry analysis, we found
more cells were proliferating in 2D-ECs than in 3D-ECs (Fig-
ures 6B and 6C). Glycolysis analysis showed that 3D-ECs
had higher glycolytic rate than 2D-ECs (Figure 6D). The
in vitro tube formation assay already showed that 3D-ECs
had longer tubes and more branches (Figure 3C). Similar
Figure 3. Properties of ECs Derived from H9 hESCs in 3D Hydrogel (3D-ECs) and 2D Culture (2D-ECs)
(A) Both ECs uptake fluorescence-labeled acetylated LDL (Ac-LDL). Scale bar, 25 mm.
(B–D) Both form tube network (B) when plated on Matrigel for 24 hr. The tube length (mm/field) and branches (C) are calculated using the
Angiogenesis Analyzer of the ImageJ software. The co-plated vascular smooth muscle cells attach to the ECs (D). Data are represented as
means ± SD of three independent replicates (n = 3). Scale bars, 50 mm. *p < 0.05, **p < 0.01.
(E) TEER properties of HUVECs, 3D-ECs and 2D-ECs, either untreated or treated with 100 ng/mL tumor necrosis factor alpha (TNF-a),
100 ng/mL IL-1b, or 100 ng/mL VEGFA, are similar. Data are represented as means ± SD of three independent replicates (n = 3).
***p < 0.001.
(F and G) When transplanted subcutaneously with a Matrigel matrix, 2D-ECs (F) and 3D-ECs (G) form vascular structures. Scale bars, 100 and
25 mm.
(H and I) qRT-PCR shows that 3D-ECs have higher expression of some key genes related to ECs, including EC markers (H), growth factors and
ECM genes (I). Data are represented as means ± SD of three independent replicates (n = 3). ***p < 0.001.
Figure 4. Whole Transcriptome Analysis
of 3D-ECs and 2D-ECs Derived from H9s
(A and B) Global heatmap of expressed genes
(A) and principal-component analysis (PCA)
(B) of 3D-ECs and 2D-ECs.
(C and D) The global gene expression cor-
relation coefficients (C) and scatterplot in
log scale of gene expression (D) between 3D-
ECs and 2D-ECs. Three biological replicates
are used for each sample.
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results were found in ECs derived from iPSCs (Figures S5 and
S6). These in vitro phenotypic analyses well supported the
RNA-seq data (Figures 5 and S7). However, the in vivoMatri-
gel Plug Assay didnot find significant differences in terms of
the vascular density and branches for 3D-ECs and 2D-ECs
(Figures 3F, 3G, and S5E). This indicates that the gene
expression and in vitro phenotype differences are not suffi-
cient to generate functional differences in vivo. Alterna-
tively, the Matrigel Plug Assay is not sensitive enough to
detect the functional differences in vivo. The functional
differences of 3D-ECs and 2D-ECs, such as integration and
potency, should be systematically studied with disease
(e.g., limb ischemia model) or developmental models in
the future (Cooke and Losordo, 2015; Tang et al., 2011).
Scalable Production of hPSC-ECs in Suspension with
the Hydrogel Scaffold
All the above studieswere performedbycasting the thermor-
eversible hydrogel (with cells encapsulated) as a thin layer
(e.g., 500–1,000 mm thickness) on cell culture plates (e.g.,
6-well plates).We also demonstrated that thehydrogel could
be processed into small fibers (with cells encapsulated in the
fibers) for suspension culturing (Figure 7A). It is generally
accepted that 3D suspension culturing is more suitable for
large-scale production of cells. On day 0, single hPSCs
(4.0 3 106 cells) were mixed with 4 mL 10% PNIPAAm-
PEG solution at 4C and injected into room temperature
E8 medium contained in a closed and sterile bioreactor
(e.g., a 50-mL conical tube). Fibroushydrogelswere instantly
formed with single hPSCs uniformly distributed in the hy-
drogels. Cells were cultured in a cell culture incubator at
37C and 5%CO2. Themediumwas stocked in a gas-perme-
able bag and continuously perfused into the bioreactor.
Perfusion instead of stirring was used to mix the medium
since the hydrogel fibers were soft and stirring resulted in fi-
ber breakage. Cells were expanded for 5 days and thendiffer-
entiated for 5 days. Onday 10, hydrogel scaffoldswere lique-
fied, andcell spheroidswerepelletedbyspinning for 5minat
1003 g. Spheroids were dissociated into single cells by treat-
ing with Accutase at 37C for 10 min. About 8.0 3 107 ECs
were produced.Magnetic beads coated with anti-CD144 an-
tibodieswere thenadded to theconical tube topulldownthe
ECswith amagnetic cell separator (Figure 7B). Live/dead cell
staining showed that the majority of the cells were live (Fig-
ure 7C). Immunostaining and flow cytometry analysis
showed that 81.3% of the day 10 cells were ECs (Figures 7D
and 7E).When transplanted subcutaneouslywith aMatrigel
matrix, ECs formed nice vascular structures (Figure 7F).
DISCUSSION
Currently, hPSC-derived ECs are made either in 2D culture
or as EBs in 3D suspension culture. Both have difficulty to
Figure 5. Differential Gene Expression Analysis between 3D-ECs and 2D-ECs Derived from H9s
(A) Gene Ontology terms that have significant differentially expressed genes.
(B–F) Log2 (expression level in 3D-ECs/expression level in 2D-ECs) of extracellular matrix genes including collagen (B), laminin (C),
integrin (D), other ECM components (E) and proteases (F).
(G–L) Log2 (expression level in 3D-ECs/expression level in 2D-ECs) of genes related to EC secretome (G), growth factors (H), chemokines
(I), cytokines (J), proliferation (K), and glycolysis (L). Three biological replicates are used for each sample.
Figure 6. Functional Comparison of
2D-ECs and 3D-ECs
(A) Western blotting shows that 3D-ECs have
higher expression of CD31, CD144, FN,
NOTCH4, and ITGA2 than 2D-ECs.
(B and C) Immunostaining (B) and flow cy-
tometry (C) of Ki67 shows more proliferating
cells in 2D-ECs than in 3D-ECs. Scale bars,
50 mm.
(D) Glycolysis analysis shows that 3D-ECs
produce more L-lactates than 2D-ECs. Data
are represented as means ± SD of three in-
dependent replicates (n = 3). ***p < 0.001.
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Figure 7. A Prototype Bioreactor
(A) The bioreactor consists of a pump for medium perfusion, an oxygen-permeable plastic bag for stocking medium and a closed container
(e.g., a 50-mL conical tube), where hydrogel fibers with cells are suspended.
(legend continued on next page)
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cost-effectively generate large numbers of high-quality ECs
required for drug discovery, tissue engineering, and cell
therapies. Both culture methods provide culturing condi-
tions that are very different from the in vivo 3D microenvi-
ronments where cells reside (Chen et al., 2014a, 2014b;
Kraehenbuehl et al., 2011; Thomson et al., 1998; Wong
et al., 2010). 2D culturing is labor, space, and reagent
consuming and considered only suitable for preparing
low-scale cells (e.g.,%109) (Kropp et al., 2017).
3D suspension culturing has been widely studied to scale
up the production of hPSCs and their derivatives (Fridley
et al., 2012; Kinney et al., 2011; Kropp et al., 2017). How-
ever, hPSCs in suspension culturing suffer from severe
cellular agglomeration (Fridley et al., 2012; Kinney et al.,
2011; Kropp et al., 2017). The strong cell-cell interactions
make hPSCs form large agglomerates (i.e., agglomeration)
that lead to culture inhomogeneity, impaired mass trans-
port, and low culture efficiency (Fridley et al., 2012; Kinney
et al., 2011; Kropp et al., 2017). Agitation (stirring or
shaking) the culture can reduce agglomeration and
enhance mass transport (Fridley et al., 2012; Kinney
et al., 2011; Kropp et al., 2017). However, agitation gener-
ates complicate hydrodynamic conditions including me-
dium flow direction, velocity, pressure, shear force, and
chemical environment. These physical and chemical mi-
croenvironments vary spatially and temporally, generating
critical stresses in some locations (e.g., near vessel wall and
impeller tip), which induce cell death and phenotype
changes (Fridley et al., 2012; Ismadi et al., 2014; Jenkins
and Farid, 2015; Kinney et al., 2011; Kropp et al., 2017;
Lei and Schaffer, 2013; Lei et al., 2014; Serra et al., 2012;
Steiner et al., 2010).
These physical and chemical microenvironments are
sensitive to many factors, such as the bioreactor design
(e.g., impeller geometry, size and position, vessel geometry
and size, positions of probes for pH, temperature, and oxy-
gen), themedium viscosity and agitation rate (Ismadi et al.,
2014; Kropp et al., 2017). They are currently not well un-
derstood and hard to control (Fridley et al., 2012; Ismadi
et al., 2014; Kinney et al., 2011; Kropp et al., 2017). In addi-
tion, how these physical and chemical factors, individually
or combined, influence different types of cells is not well
understood and hard to study. These knowledge gaps lead
to large culture variations between batches as well as diffi-
culty in scaling up. The challenge of using 3D suspension
culturing for large-scale cell production is well demon-
strated by a few recent studies on producing hPSC-derived
cardiomyocytes in stirred-tank bioreactors (Chen et al.,
2015; Jara-avaca et al., 2014). For three independent
batches (100 mL culture volume) with HES3 hESCs,
both the yield and product purity varied in large ranges
(e.g., from 40 million to 100 million cells for the yield,
and from 54% to 84% for the cardiomyocyte purity). Using
the same bioreactor and a different hPSC line, the final
yield ranged from 89 million to 125 million cells, and final
cardiomyocyte purity ranged from 28% to 88% (Chen
et al., 2015; Jara-avaca et al., 2014). In addition, when cul-
ture volume was scaled from 100 to 1,000 mL, the yield
and differentiation efficiency were significantly changed
(Chen et al., 2015; Jara-avaca et al., 2014). This makes
scaling up very challenging since optimizing multiple fac-
tors in large culture volumes is costly. To the best of our
knowledge, the largest demonstrated culture volume for
hPSCs and their derivative in literature is less than 10 L
(Kempf et al., 2016; Kropp et al., 2017). In short, the uncon-
trolled cell aggregation and hydrodynamic stress/condi-
tionsmake it difficult to culture hPSCs and their derivatives
on a large scale with 3D suspension culturing.
The thermoreversible hydrogel scaffold used in this pa-
per not only provides 3D space for cell growth, but also
acts a physical barrier to prevent cell agglomeration and
isolate the shear force (Figure 1). Eliminating these negative
factors leads to significantly enhanced culture efficiency.
We showed that ECs could be produced with high viability,
high purity (>80%), and high yield (2.0 3 107 cells/mL
hydrogel) within 10 days. For comparison, it usually yields
1.0 3 106 to 2.0 3 106 cells/mL in 3D suspension cultures
(Lei et al., 2014; Serra et al., 2012; Steiner et al., 2010;
Wurm, 2004). In addition, the synthetic hydrogel is chem-
ically defined. Due to its thermoreversible nature, seeding
and harvesting cells are simple and scalable. The system
can be adapted to multiple scales—from the laboratory
and toward the clinic—to support research in cell thera-
pies, tissue engineering, and high-throughput drug discov-
ery with hPSC-ECs. For instance, 50 mL hydrogel would
be sufficient to produce 109 ECs for preclinical animal
studies, and a bioreactor with 5 L of hydrogel could
yield >1011 ECs for clinical studies. The ability to move a
(B) On day 0, single hPSCs are mixed with 10% PNIPAAm-PEG solution at 4C and injected into the room-temperature E8 medium in the
container. Fibrous hydrogels are instantly formed. Cells are cultured in E8 medium for 5 days, followed by an additional 5 days in EC
differentiation medium. Medium is continuously perfused. On day 10, the hydrogel scaffold is liquefied, and spheroids are pelleted by
centrifugation. Spheroids are dissociated into single cells by incubating in Accutase at 37C for 10 min. Magnetic beads coated with anti-
CD144 were added to pull down the CD144+ cells.
(C–E) Live/dead staining (C), immunostaining (D), and flow cytometry analysis (E) of day 10 cells. Scale bars, 200 and 100 mm.
(F) When transplanted subcutaneously with a Matrigel matrix, ECs form nice vascular structures. H9s are used in this figure. Scale bar,
50 mm.
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single-culture system throughmultiple scales may aid clin-
ical development.
Conclusion
We developed a scalable and GMP-compliant method for
manufacturing ECs from hPSCs with high viability, high
purity (>80%), and high yield (2.0 3 107 cells/mL hydro-
gel). These ECs had similar properties as ECsmade using 2D
culture systems. The method will make ECs broadly avail-
able and affordable for various applications.
EXPERIMENTAL PROCEDURES
hPSCs Culture
H9 hESCs (WiCell, no. WA09) were purchased from WiCell
Research Institute. iPSCs were obtained from the Human Embry-
onic Stem Cell Core, Harvard Medical School. MSC-iPSCs and
Fib-iPSCs were reprogrammed from mesenchymal stem cells and
fibroblasts, respectively, by the George Q. Daley Lab (Children’s
Hospital Boston, MA), and have been well characterized and
described in the literature (Park et al., 2008). hPSCs (H9s and iPSCs)
were maintained in a six-well plate coated with Matrigel (BD Bio-
sciences, no. 354277) in E8 medium (Invitrogen, no. A1517001).
Cells were passaged every 4 days with 0.5 mM EDTA (Invitrogen,
no. AM9260G). The medium was changed daily. Cells were
routinely checked for the expression of pluripotency markers,
OCT3/4 and NANOG, their capability to form teratomas in immu-
nodeficient mice, their karyotypes, and bacterial contaminations.
Human aortic vascular smooth muscle cells (no. CC-2571) and
HUVECs (no. 00191027) were from Lonza.
Culturing hPSCs in 3D PNIPAAm-PEG Hydrogels
To transfer the culture from 2D to 3D PNIPAAm-PEG hydrogels
(Cosmo Bio, no. MBG-PMW20-5005), hPSCs maintained inMatri-
gel-coated six-well plates were treated with Accutase (Life Technol-
ogies, no. A1110501) at 37C for 5 min and dissociated into single
cells (Lei and Schaffer, 2013; Lei et al., 2014). Dissociated cells were
mixed with 10% PNIPAAm-PEG solution dissolved in E8 medium
on ice and cast on tissue culture plates, then incubated at 37C for
10min to formhydrogels before addingwarmE8mediumcontain-
ing 10 mM ROCK inhibitor ([RI], Y-27632, LC Laboratories, no.
Y5301). Themediumwas changed daily. Cells were passaged every
5 days. To passage cells, the medium was removed, and 2 mL ice-
cold PBS was added to dissolve the hydrogel for 5 min. Cell spher-
oids were collected by spinning at 100 3 g for 3 min. Cells were
incubated in Accutase at 37C for 10 min and dissociated into
single cells.
ECDifferentiation in 2DCultures and in 3DHydrogels
For 2D endothelial cell differentiation, hPSCs were dissoci-
ated with Accutase and plated on Matrigel at a density of
40,000 cells/cm2 in E8 medium with 10 mM RI. After 24 hr, the
medium was replaced with differentiation medium, consisting of
N2B27 medium (1:1 mixture of DMEM/F12 [HyClone, no.
SH30004.04] with Glutamax-I [Life Technologies, no. 35050061]
and Neurobasal medium [Life Technologies, no. 21103049] sup-
plemented with N2 [Life Technologies, no. 17502048] and
B27 minus vitamin A [Life Technologies, no. 12587010] with
8 mM CHIR99021 [LC Laboratories, no. C6556] and 25 ng/mL
BMP4 [R&D Systems, no. 314BP010]). After 3 days, the differenti-
ation medium was replaced by EC induction medium consisting
of StemPro-34 SFM medium (Life Technologies, no. 10639011)
supplemented with 200 ng/mL VEGFA (PeproTech, no. 100-20)
and 2 mM Forskolin (Sigma, no. F3917). The induction medium
was changed after 1 day. ECs were harvested for analysis on day 5.
For EC differentiation in 3D PEG hydrogel, single hPSCs were
mixed with 10% PNIPAAm-PEG solution and cast on tissue culture
plate, then incubated at 37C for 10 min to form hydrogels before
adding warm E8 medium containing 10 mM RI. Medium was
changed daily. hPSCs were expanded for 5 days. E8 medium was
removed and replaced with EC differentiation medium. After
3 days, the differentiation medium was replaced by EC induction
medium. The induction medium was changed after 1 day. Cells
were harvested for analysis on day 5.
Suspension Culturing in the Bioreactor
The bioreactor consists of a pump for medium perfusion, an oxy-
gen-permeable plastic bag for stocking medium and a closed
container (e.g., a 50-mL conical tube with a septa cap). On day 0,
single iPSCs (4.0 3 106 cells) were mixed with 4 mL 10%
PNIPAAm-PEG solution at 4C and were injected into room-tem-
perature E8 medium in the container. Fibrous hydrogels (with
diameter <1.0 mm) were instantly formed. Cells were cultured in
E8 medium for 5 days, followed by an additional 5 days of EC dif-
ferentiationmedium.Mediumwas continuously perfused. On day
10, hydrogel scaffolds were liquefied by perfusing ice-cold PBS.
Spheroids were pelleted by centrifugation. Spheroids were dissoci-
ated into single cells by incubating in Accutase at 37C for 10min.
Magnetic beads coated with anti-CD144 antibodies (Miltenyi Bio-
tec, cat. no. 130-097-857) were added to pull downECswith amag-
netic cell separator. The bioprocess was repeated twice.
Immunocytochemistry and Flow Cytometry
For 2D immunostaining, cells were fixed with 4% paraformalde-
hyde (PFA) at room temperature for 20 min, permeabilized with
0.25% Triton X-100 for 30 min and blocked with 5% donkey
serum for 1 hr before incubating with primary antibodies
(Table S1) at 4C overnight. After extensive washing, secondary
antibodies (Table S1) and 10 mM, DAPI in 2% BSA was added and
incubated at room temperature for 4 hr. Cells were washed with
PBS three times before imaging.
For 3D immunostaining (spheroids), hPSCs were fixed with 4%
PFA at room temperature for 30 min, and then incubated with
PBS+ 0.25% Triton X-100+ 5% (vol/vol) goat serum+ primary
antibodies at 4C for 48 hr. After extensive washing, secondary
antibodies in 2% BSA were added and incubated at 4C for 24 hr.
Cells were washed with PBS three times before imaging with a
confocal microscope.
For flow cytometry analysis, the harvested cells were dissociated
into single cells with Accutase. Single cells were fixed with 4%
PFA and stained with primary antibodies (Table S1) at 4C over-
night. After washing (three times) with 1% BSA in PBS, secondary
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antibodies were added and incubated at room temperature for 2 hr.
Cells were washed with 1% BSA in PBS and analyzed using Cytek
flow cytometry. Single-color and isotype controls served as
compensation and negative gating.
RNA Extraction, cDNA Synthesis, and qPCR
Total RNAs for qPCR and RNA-Seqwere extracted from2D-ECs and
3D-ECs on day 5 of the differentiation using TRIzol (Invitrogen,
no. 15596018), according to the manufacturer’s instructions.
Reverse transcription is done with the Maxima First Strand cDNA
Synthesis Kit (Life Technologies, no. K1642). Real-time qPCR was
carried out in an Eppendorf MasterCycler RealPlex4 (Thermo
Fisher Scientific) using the Power SYBR Green PCR Master Mix
(Thermo Fisher Scientific, no. 4367659), according to the manu-
facturer’s instructions. The data were normalized to the endoge-
nous GAPDH. Primer sequence was listed in Table S2.
EB Differentiation
hPSCs were suspended in DMEM+ 20% FBS+ 10 mM b-mercaptoe-
thanol in a low adhesionplate for 6 days. The cellmasseswere then
transferred into plates coatedwith 0.1% gelatin and cultured in the
samemedium for another 6 days, followed by fixation and staining
as described above.
Teratoma Formation In Vivo
The animal experiments were carried out following the protocols
approved by the University of Nebraska–Lincoln Animal Care
and Use Committee. hPSCs (3.0 3 106) were suspended in 25 mL
PBS+ 25 mL Matrigel and injected subcutaneously at the back of
the neck of the non-obese diabetic/severe combined immunodefi-
ciency mice (female, age 7 weeks, Charles River Laboratory). Tera-
tomawas harvestedwhen its size reached 2 cm. Teratomawas fixed
with 4% PFA for 48 hr, dehydrated with 70%, 95%, and 100%
ethanol sequentially, and de-fated with xylene for 2 hr before
embedded in paraffin. A 10-mm-thick section was cut and stained
with H&E.
Statistical Analysis
Statistical analyses were done using the statistical package Instat
(GraphPad Software, La Jolla, CA). For multiple comparisons, the
means of triplicate samples were compared using the Tukey multi-
ple comparisons analysis with the alpha level indicated in the
figure legend.
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